PRESS RELEASE: Covaris Announces Growth Partnership with New Mountain Capital
January 13, 2022PRESS RELEASE: PacBio and Covaris Announce Joint Workflow Enabling HiFi Sequencing of FFPE Tumor Samples
April 15, 2026Covaris Headquarters and Manufacturing Facility Relocation
We are excited to announce that Covaris’ headquarters and primary manufacturing operations are moving to a new facility around the first week of November 2026. Our new address will be:
Covaris, LLC
3 Van de Graaff Drive, Suite 103
Burlington, MA 01803
In October, please update your records to reflect this new location for all future correspondence, deliveries, and invoicing. Our phone numbers, email addresses, website and UK offices will remain unchanged. We will communicate further specifics as construction and move dates are finalized. Please monitor our website for updates.
- What this means for our operations:
- Uninterrupted Supply: We have carefully planned this transition in phases to ensure there is no disruption to our manufacturing schedule, product availability, or fulfillment processes.
- Enhanced Capabilities: This new footprint allows us to modernize and scale our production capacity and continue delivering the high-quality multiomics solutions you rely on.
We deeply value our continued partnership and are committed to making this transition as seamless as possible for your team. If you have any questions or require further clarification regarding specific purchase orders, shipping logistics, or billing, please reach out to your dedicated territory manager or our support team at [email protected].
Thank you for your ongoing support and trust in Covaris. We look forward to continuing to work with you from our new headquarters.